AbbVie Reports real-world evidence Data for Capmatinib in Alzheimer's disease

AbbVie today announced real-world evidence results for Capmatinib in patients with Alzheimer's disease. The study demonstrated that Capmatinib provides durable benefit over long-term follow-up compared to standard of care or placebo. These results provide important insights into the treatment of Alzheimer's disease and support the continued development of Capmatinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Capmatinib was consistent with previous observations, with no new safety signals identified.